41st Annual Miami Breast Cancer Conference® - Abstracts

62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population

ByKseniya Roudakova,Cristina Solis-Pomales,Amy Jeng,J. Jaime Alberty-Oller

May 9th 2024

63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients

ByTrevor F. Roush,Susan K. Boolbol, MD,Carinne W. Anderson

May 8th 2024

64 Empowering Medical Students to Deliver Breast Health Education: A Community-Based Initiative

ByArianna Tapia,Alyssa Pereslete,Rachel Siretskiy,Catarina Jim,Erica Merlino,Rachel Clarke,Prasad Bhoite,Julia Bisschops

May 8th 2024

65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices

BySandhya Mehta,Anupama Vasudevan,John Li,Dawn Brenneman,Jackie Kwong

May 7th 2024

66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study

ByPat W. Whitworth,Steven C. Shivers,Chirag Shah, MD,Rakesh Patel,Charles E. Cox, MS, FACS,Karuna Mittal,Troy Bremer

May 5th 2024

67 Disparities in Regional Anesthesia Block Acceptance for Mastectomy With Reconstruction Surgery in a Standardized Setting

ByHanae Tokita,Perri Vingan,Joanna Serafin,Lily Boe,Jonas Nelson

May 4th 2024

68 Magnetic Tracer Increases Surgical Productivity and Reduces Time to Surgery When Compared With Standard Lymph Node Mapping Modalities

ByRhiana Menen,Sytoria Zigmund

May 2nd 2024

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

ByAttilla Soran,Berk Goktepe,Berkay Demirors,Serdar Ozbas,Efe Sezgin,Jamila Al-Azhri,Shruti Zaveri,S. Meas,Anthony Lucci, MD,Priscilla F. Mcauliffe, MD, PhD

April 21st 2024

70 Navigating Lymphedema: The Impact of Indocyanine Green Lymphography (ICG_L) on Personalized Therapy Outcomes in Patients With Breast Cancer (BC)

ByAttilla Soran,Wendy Rodriguez,Kazim Senol

April 20th 2024

71 Utility of Performing Staging MRI in Breast Cancer Patients Over the Age of 75

ByAshlee Rice,Kendra Winter,Lina Sizer,Catherine Carruthers,Eunice Shin,W. Bradford Carter

April 14th 2024

72 A Novel Biosignature for Early- Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast- Conserving Surgery

ByTroy Bremer,Karuna Mittal,Chirag Shah, MD,Frank Vicini, MD,Naamit Gerber,Melissa Krystel-Whittemore,Clayton C. Yates,Balusubramanyam Karanam,Geza Acs,Elizabeth Pernicone,Melissa Tempest,Charles E. Cox, MS, FACS,Steven C. Shivers,Lotta Wadsten

April 13th 2024

41st Annual Miami Breast Cancer Conference® - Abstracts

62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population

63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients

64 Empowering Medical Students to Deliver Breast Health Education: A Community-Based Initiative

65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices

66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study

67 Disparities in Regional Anesthesia Block Acceptance for Mastectomy With Reconstruction Surgery in a Standardized Setting

68 Magnetic Tracer Increases Surgical Productivity and Reduces Time to Surgery When Compared With Standard Lymph Node Mapping Modalities

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

70 Navigating Lymphedema: The Impact of Indocyanine Green Lymphography (ICG_L) on Personalized Therapy Outcomes in Patients With Breast Cancer (BC)

71 Utility of Performing Staging MRI in Breast Cancer Patients Over the Age of 75

72 A Novel Biosignature for Early- Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast- Conserving Surgery

Trending on CancerNetwork

Poorer Outcomes Observed for Black Patients Undergoing Chemotherapy for AML

Fixed-Duration Venetoclax Combos Show Noninferior PFS to Ibrutinib in CLL

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Survival Benefit Seen With Cilta-Cel in Earlier Lines of Myeloma Treatment

How Has Teclistamab Administration Translated Into Community MM Settings?